Earlier quoted context omitted.
You and Rick are incorrect. The pure research part is, as stated, a small part of the costs, but 2/3 of that amount is not dedicated to patent applications, and of the remainder the bulk of it is taken up by the costs of testing. Marketing is a large part of the costs, but it is not the largest component. > I may be wrong on each point, You are.
I made another point: that the bulk of pharmaceutical business may not be really useful, or at least not critical (cosmetics and such). Did you say I am wrong on this point as well? Anyway, I am quite ignorant. Do you have any references I could read so I have a better understanding of the problem? Thank you.
Cosmetics? What cosmetics does Abbott make?
To the extent that the argument has any connection to reality, it's a combintation of irrelevant and wrong.
If you don't want to pay the costs of "cosmetics", don't buy them.
To the extent that there's any cross-subsidization in Pharma, it goes from the "non-essential but popular" to the critical. In other words, you've got it backwards.